Targeting neuroinflammation by pharmacologic down-regulation of inflammatory pathways is neuroprotective in protein misfolding disorders.

Neuroinflammation plays a crucial role in the development of neurodegenerative protein misfolding disorders. This category of progressive diseases includes, but is not limited to, Alzheimers disease, Parkinsons disease, and prion diseases. Shared pathogenesis involves the accumulation of misfolded proteins, chronic neuroinflammation, and synaptic dysfunction, ultimately leading to irreversible neuronal loss, measurable cognitive deficits, and death. Presently, there are little to no effective treatments to halt the advancement of neurodegenerative diseases. We hypothesized directly targeting neuroinflammation by downregulating the transcription factor, NF-{kappa}B and the inflammasome protein, NLRP3, with the brain-penetrant, non-toxic, SB_NI_112, would be neuroprotective. To achieve this, we used a cocktail of RNA targeting therapeutics (SB_NI_112) shown to be brain-penetrant, non-toxic, and targeting both NF-|B and NLRP3. We utilized a mouse-adapted prion strain as a model for neurodegenerative diseases to assess aggregation of misfolded proteins, glial inflammation, neuronal loss, cognitive deficits, and lifespan. Prion-diseased mice were treated either intraperitoneally or intranasally with SB_NI_112. Behavioral and cognitive deficits were significantly protected by this combination of NF-{kappa}B and NLRP3 down-regulators. Treatment reduced glial inflammation, protected against neuronal loss, prevented spongiotic change, rescued cognitive deficits, and significantly lengthened lifespan of prion-diseased mice. We have identified a non-toxic, systemic pharmacologic that down-regulates NF-|B and NLRP3, prevents neuronal death and slows the progression of neurodegenerative disease. Though mouse models do not always predict human patient success, and the study was limited due to sample size and number of dosing methods utilized, these findings serve as a proof of principle for continued translation of the therapeutic SB_NI_112 for prion disease and other neurodegenerative diseases. Based on success in a murine prion model, we will be continual testing SB_NI_112 in a variety of neurodegenerative disease models, including Alzheimers Disease and Parkinsons Disease.